These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30896540)

  • 1. Clinical Trials of Repurposing Medicines in Acute Myeloid Leukemia: Limitations and Possibilities in the Age of Precision Therapy.
    Andresen V; Gjertsen BT
    Cancer J; 2019; 25(2):153-163. PubMed ID: 30896540
    [No Abstract]   [Full Text] [Related]  

  • 2. Transcriptome Signature Reversion as a Method to Reposition Drugs Against Cancer for Precision Oncology.
    Koudijs KKM; Terwisscha van Scheltinga AGT; Böhringer S; Schimmel KJM; Guchelaar HJ
    Cancer J; 2019; 25(2):116-120. PubMed ID: 30896533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accelerating Precision Drug Development and Drug Repurposing by Leveraging Human Genetics.
    Pulley JM; Shirey-Rice JK; Lavieri RR; Jerome RN; Zaleski NM; Aronoff DM; Bastarache L; Niu X; Holroyd KJ; Roden DM; Skaar EP; Niswender CM; Marnett LJ; Lindsley CW; Ekstrom LB; Bentley AR; Bernard GR; Hong CC; Denny JC
    Assay Drug Dev Technol; 2017 Apr; 15(3):113-119. PubMed ID: 28379727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalized therapy for acute myeloid leukemia.
    Hourigan CS; Karp JE
    Cancer Discov; 2013 Dec; 3(12):1336-8. PubMed ID: 24327695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of Drug Repurposing-Based Precision Medicine Platform for Leukaemia Patient Treatment.
    Kenmogne VL; Nweke EE; Takundwa MM; Fru PN; Thimiri Govinda Raj DB
    Adv Exp Med Biol; 2023; 1410():115-126. PubMed ID: 36289161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrative methods for analyzing big data in precision medicine.
    Gligorijević V; Malod-Dognin N; Pržulj N
    Proteomics; 2016 Mar; 16(5):741-58. PubMed ID: 26677817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in patient care through increasingly individualized therapy.
    DiNardo CD; Perl AE
    Nat Rev Clin Oncol; 2019 Feb; 16(2):73-74. PubMed ID: 30602758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Turning omics data into therapeutic insights.
    Kedaigle A; Fraenkel E
    Curr Opin Pharmacol; 2018 Oct; 42():95-101. PubMed ID: 30149217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precision medicine for acute myeloid leukemia.
    Lai C; Karp JE; Hourigan CS
    Expert Rev Hematol; 2016 Jan; 9(1):1-3. PubMed ID: 26514194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precision therapy for acute myeloid leukemia.
    Yang X; Wang J
    J Hematol Oncol; 2018 Jan; 11(1):3. PubMed ID: 29301553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Network-Based Drug Repositioning: Approaches, Resources, and Research Directions.
    Alaimo S; Pulvirenti A
    Methods Mol Biol; 2019; 1903():97-113. PubMed ID: 30547438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of acute myeloid leukemia in the next decade - Towards real-time functional testing and personalized medicine.
    Lam SS; He AB; Leung AY
    Blood Rev; 2017 Nov; 31(6):418-425. PubMed ID: 28797519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New drugs for acute myeloid leukemia inspired by genomics and when to use them.
    Pollyea DA
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):45-50. PubMed ID: 30504290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of precision therapies for rare inborn errors of metabolism: Functional investigations in cell culture models.
    Didiasova M; Banning A; Tikkanen R
    J Inherit Metab Dis; 2024 May; 47(3):509-516. PubMed ID: 37606592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are we ready for precision medicine in acute myeloid leukemia?
    Roboz GJ
    Clin Adv Hematol Oncol; 2016 Aug; 14(8):582-4. PubMed ID: 27487100
    [No Abstract]   [Full Text] [Related]  

  • 16. Personalizing Chinese medicine by integrating molecular features of diseases and herb ingredient information: application to acute myeloid leukemia.
    Huang L; Li H; Xie D; Shi T; Wen C
    Oncotarget; 2017 Jun; 8(26):43579-43591. PubMed ID: 28454110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational drug repositioning for rare diseases in the era of precision medicine.
    Delavan B; Roberts R; Huang R; Bao W; Tong W; Liu Z
    Drug Discov Today; 2018 Feb; 23(2):382-394. PubMed ID: 29055182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy of older persons with acute myeloid leukaemia.
    Krug U; Gale RP; Berdel WE; Müller-Tidow C; Stelljes M; Metzeler K; Sauerland MC; Hiddemann W; Büchner T
    Leuk Res; 2017 Sep; 60():1-10. PubMed ID: 28618329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Precision medicine in acute myeloid leukemia: Hope, hype or both?
    Prasad V; Gale RP
    Leuk Res; 2016 Sep; 48():73-7. PubMed ID: 27497757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MD-Miner: a network-based approach for personalized drug repositioning.
    Wu H; Miller E; Wijegunawardana D; Regan K; Payne PRO; Li F
    BMC Syst Biol; 2017 Oct; 11(Suppl 5):86. PubMed ID: 28984195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.